SCHEMBL6437562

SCHEMBL6437562

CNCCOc1cccc(-c2ccc(C3CCN(S(=O)(=O)C(C)(C)C(=O)OC)CC3)cc2C)c1

nearest known ligand 0.84

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 10/20 0.84
MMP3 P08254 10/20 0.84
MMP1 P03956 2/20 0.72
MMP9 P14780 2/20 0.72
MMP14 P50281 2/20 0.72
TLR9 Q9NR96 1/20 0.38
TLR7 Q9NYK1 1/20 0.38
USP5 P45974 1/20 0.35
KDM4E B2RXH2 2/20 0.35
AVPR1B P47901 1/20 0.34
NSD2 O96028 1/20 0.34
ALDH1A1 P00352 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PKM P14618 1/20 0.34
HTR7 P34969 1/20 0.34
DHODH Q02127 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6586333 0.92 MMP2 (0.85) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6972635 0.91 MMP3 (1.00) MMP2MMP3MMP1MMP9MMP14
Hydrochloric Acid SCHEMBL6434162 0.91 MMP2 (0.83) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6434351 0.91 MMP2 (0.84) MMP2MMP3MMP1MMP9MMP14
Hydrochloric Acid SCHEMBL6962275 0.91 MMP3 (0.98) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6587846 0.90 MMP2 (0.83) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6433148 0.90 MMP2 (0.69) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6436990 0.88 MMP3 (0.69) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6432618 0.87 MMP2 (0.67) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6971949 0.86 MMP2 (0.68) MMP2MMP3MMP1MMP9MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1181017-B1 METALLOPROTEASE INHIBITORS PFIZER LTD (GB) 2003-04-16 EP disclosed
US-6511993-B1 Substituted alpha-aminosulphonyl-acetohydroxamic acids which are inhibitors of zinc-dependent metalloprotease enzymes PFIZER INC. 2003-01-28 US disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 MMP2 19/4885MMP3 28/4885MMP1 1/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 MMP2 19/4885MMP3 28/4885MMP1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.